Meitheal Pharmaceuticals (Meitheal) is pleased to announce the official launch of Paclitaxel:
- 71288-183-50: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100mg per vial SDV
ABOUT PACLITAXEL FOR INJECTABLE SUSPENSION
Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is a microtubule inhibitor indicated for metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin. Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
Do not substitute paclitaxel protein-bound particles for injectable suspension (albumin-bound) for other paclitaxel products.
- Extravasation: Closely monitor the infusion site for extravasation and infiltration.
- Metastatic Breast Cancer (MBC): Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 260 mg/m2 intravenously over 30 minutes every 3 weeks.
- Non-Small Cell Lung Cancer (NSCLC): Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 100 mg/m2 intravenously over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after paclitaxel protein-bound particles for injectable suspension (albumin-bound).
- Adenocarcinoma of the Pancreas: Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 125 mg/m2 intravenously over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8 and 15 of each 28-day cycle immediately after paclitaxel protein-bound particles for injectable suspension (albumin-bound).
- Use in patients with Hepatic Impairment: Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is not recommended for use in patients with AST > 10 x ULN; or bilirubin > 5 x ULN or with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment. For MBC or NSCLC, reduce starting dose in patients with moderate to severe hepatic impairment.
- Dose Reductions for Adverse Reactions: Dose reductions or discontinuation may be needed based on severe hematologic, neurologic, cutaneous, or gastrointestinal toxicities.
For full prescribing information, please click on the following link.
Learn more about who we are and what we do at: www.meithealpharma.com.
